cancer cancer guidelines clinical trials cancer patients oncology cancer physicians cancer hospitals oncology
NCCN - National Comprehensive Cancer Network National Comprehensive Cancer Network Homepage Patients with Cancer Cancer Clinicians Cancer Industry About National Comprehensive Cancer Network

 

Contact Us / Privacy Policy

Find an NCCN Member Institution


UCSF Comprehensive Cancer Center Home Page

Profile


Find a Clinical Trial

Adult Oncology Services

Introduction

General Information

Treatment

Cancer Prevention and Screening

Support Services

Supportive Care

Clinical and Research Efforts


Pediatric Oncology Services
UCSF Helen Diller Family Comprehensive Cancer Center

Introduction

General Information

Clinical and Research Information

Special Expertise

Statistics


Genetic Counseling and Testing Service

Introduction

Intake Process

Testing

Post-Test Counseling and Follow-Up

Research


Go back to previous page

 

 

     
  UCSF Helen Diller Family Comprehensive Cancer Center

For information on clinical trials at this NCCN Member Institution click here.

The University of California, San Francisco is an international leader in cancer research and patient care. The mission of the UCSF Helen Diller Family Comprehensive Cancer Center’s clinical program is to provide comprehensive care through multidisciplinary collaboration and integrated services, to advance cancer therapies through clinical research, and to train future leaders in the treatment of patients with cancer. The collaborative approach to research and treatment is a hallmark of this program, enlisting the participation of surgeons, medical oncologists, radiation oncologists, pediatric oncologists, radiologists, and pathologists. Together with renowned UCSF investigators in fields ranging from molecular biology and biochemistry to epidemiology, biostatistics, and public policy analysis, UCSF clinical specialists are committed to translating scientific insights into lifesaving realities for cancer patients everywhere.

Highlights of the Center’s comprehensive clinical program include:

  • Translational research and innovative combined-modality trials for management of cancers of the prostate, breast, head and neck, colon, liver, lung, melanoma, and other solid tumors.
  • Premier bone marrow transplantation.
  • Highly advanced radiation therapy techniques including conformal radiotherapy, intraoperative radiotherapy, high-dose brachytherapy, intravascular brachytherapy, stereotactic radiotherapy, and radio-immunotherapy.
  • World-renowned neuro-oncology program providing innovative therapy for brain and spinal cord cancers.
  • Risk prevention/genetic screening.
  • Specialized therapy for AIDS-related malignancies.
  • Leaders in the treatment of pediatric malignancies.

UCSF’s basic research on cancer follows in the tradition of J. Michael Bishop, MD, and Harold E. Varmus, MD, Nobel Prize recipients in 1989 for their work at UCSF on oncogenes. The Cancer Center received comprehensive designation from the National Cancer Institute in 1999, making it the only NCI-designated comprehensive cancer center from Seattle to Los Angeles. In November 2007 the Center was renamed the Helen Diller Family Comprehensive Cancer Center.  Particular foci of multidisciplinary research have been recognized by an NCI Specialized Program of Research Excellence (SPORE) in breast cancer, first awarded in 1992; a SPORE in prostate cancer, awarded in 2000; and a SPORE in brain cancer, awarded in 2002. Also integral to the Center’s programs are activities related to tobacco control, with projects ranging from laboratory science to public policy.

Current grant funding to UCSF investigators for cancer research projects from all sources totals $181.5 million annually.  In 2006, UCSF ranked 8th among all 740 National Cancer Institute grantee institutions, with 162 grants totaling $64.8 million.


UCSF Helen Diller Family Comprehensive Cancer Center
Adult Oncology Services

The University of California, San Francisco is an international leader in cancer research and patient care. The mission of the UCSF Helen Diller Family Comprehensive Cancer Center’s clinical program is to provide comprehensive care through multidisciplinary collaboration and integrated services, to advance cancer therapies through clinical research, and to train future leaders in the treatment of patients with cancer. The collaborative approach to research and treatment is a hallmark of this program, enlisting the participation of surgeons, medical oncologists, radiation oncologists, pediatric oncologists, radiologists, and pathologists. Together with renowned UCSF investigators in fields ranging from molecular biology and biochemistry to epidemiology, biostatistics, and public policy analysis, UCSF clinical specialists are committed to translating scientific insights into lifesaving realities for cancer patients everywhere.

Highlights of the Center’s comprehensive clinical program include:

  • Translational research and innovative combined-modality trials for management of cancers of the prostate, breast, head and neck, colon, liver, lung, melanoma, and other solid tumors.
  • Premier bone marrow transplantation and care for hematologic malignancies.
  • Highly advanced radiation therapy techniques including conformal radiotherapy, intraoperative radiotherapy, high-dose brachytherapy, intravascular brachytherapy, stereotactic radiotherapy, and radio-immunotherapy.
  • World-renowned neuro-oncology program providing innovative therapy for brain and spinal cord cancers.
  • Cancer prevention/genetic counseling and testing for hereditary cancer syndromes.
  • Specialized therapy for AIDS-related malignancies.
  • Leaders in the treatment of pediatric malignancies.
  • Active symptom management team including psychosocial services, medicine, chaplaincy, nursing, pharmacy, and integrative medicine services.
  • Referral services and support programs including a Cancer Resource Center, Art for Recovery, and smoking cessation programs.

Multidisciplinary Teams

The UCSF Helen Diller Family Comprehensive Cancer Center provides multidisciplinary teams in breast, urologic, gastrointestinal, cutaneous, thoracic, sarcoma, and neurologic oncology. Case conferences are held on a regular schedule and as needed.

Special Expertise

Specialized expertise at UCSF includes cutting-edge techniques in radiation oncology, management of liver tumors, primary and metastatic cancer, management of endocrine tumors within a multidisciplinary setting, and new techniques including radio conjugates.


General Information

General Information

800.888.8664

Referring Physician Line

800.444.2559

Location

San Francisco, CA

Facility

Adult outpatient oncology services are concentrated at the UCSF/Mt. Zion Medical Center, where multidisciplinary clinics are housed in an 88,000-square-foot facility that encompasses radiation oncology, breast care, infusion, gastrointestinal cancers, melanoma, thoracic oncology, gynecological oncology, AIDS oncology, orthopedic oncology, tumors of the head and neck, urologic cancers, endocrine cancers, hematologic malignancies, and general oncology. Surgical oncology services are divided between the UCSF/Mt. Zion Medical Center and the UCSF Medical Center/Parnassus campus. UCSF also provides house staff and oncology services at San Francisco General Hospital and the San Francisco Veterans Affairs Medical Center.

Travel Assistance

Travel guidance, but not financial assistance, is provided to patients and caregivers by each clinical service line. For international visitors, assistance is provided through a concierge program, available at 415.353.8489.

Lodging

Assistance in arranging for off-campus lodging is provided to patients and caregivers by each clinical service line.


Treatment

Multidisciplinary Clinics

Disease Center

Contact Number

Breast Oncology

415.353.7070

Urologic Oncology

415.353.7171

GI Oncology

415.353.9888

Neurologic Oncology

415.353.2966

Head & Neck Oncology

415.885.7528

Hematology/Medical Oncology

415.353.2421

Thoracic Oncology

415.885.3882

Gynecologic Oncology

415.353.9600

Dysplasia

415.353.7100

Melanoma

415.353.9900

Cancer Risk

415.885.7779

Ocular Oncology

415.502.3206

Orthopedic Oncology

415.885.3800

Endocrine Oncology

415.353.7789

Other Cutaneous Oncology

415.353.7800

AIDS-related Malignancies

415.353.9888

 

Hematopoietic Stem Cell Transplant Program

UCSF provides Hematopoietic Stem Cell Transplant Services for adult and pediatric patients. Our programs perform autologous, related and unrelated allogeneic, and cord blood transplants to patients with a wide range of malignant and non-malignant disorders of the bone marrow and immune system.  Diseases managed include leukemia, lymphoma, myeloma, myelodysplasia, bone marrow failure states such as aplastic anemia, and selected solid tumors such as testicular cancer. In addition, the pediatric program treats patients with inherited disorders of the bone marrow or immune system, such as Fanconi’s Anemia and Severe Combined Immune Deficiency Syndrome (SCIDS).

Integrative Oncology

Complementary and alternative medical services for individuals with cancer are a collaborative effort between the UCSF Helen Diller Family Comprehensive Cancer Center and UCSF's Osher Center for Integrative Medicine.  Integrative oncology refers to the combination of evidence-based complementary therapies into the conventional cancer treatment regimen or survivorship plan.  Two board-certified UCSF oncologists provide integrative oncology consultation to patients living with and beyond cancer at the Osher Center and refer them to the Osher practitioners, who offer integrative psychiatry, psychotherapy, guided imagery, biofeedback, physical therapy, physical fitness, massage, yoga, Tai Chi, mindfulness meditation, acupuncture, and Traditional Chinese Medicine.  Clinical trials, undertaken both within the Cancer Center and the Osher Center, currently include studies of acupuncture, biofeedback, massage, botanicals, and other interventions.  Appointments for consultations at the Osher Center can be arranged by phone or e-mail: 415.353.7720, integrate@ocim.ucsf.edu.

Late Effects Clinic

Currently, UCSF follows survivors of childhood cancer who have been treated at UCSF until age 21–30 for second malignancies and other side effects of cancer therapy. We have a Childhood Cancer Survivor Clinic, a formal Late Effects Clinic, which operates under the leadership of Robert Goldsby, MD.


Cancer Prevention and Screening

Cancer prevention topics figure prominently among lunchtime lectures that are presented regularly at two campus locations and geared to members of the lay community. Additional education events, often produced in coalition with community partners, include an annual day-long women's health forum on breast and gynecologic cancers, an annual symposium on fighting cancer in the African-American community (including free screening for PSA levels), and drop-in skin cancer screening in observance of Melanoma Awareness Month. Ongoing smoking-cessation programs are offered through the UCSF Cancer Resource Center (415.885.3693, crc@ucsfmedctr.org). The Cancer Resource Center also has a dedicated dietitian who provides individual nutrition counseling and conducts a variety of public education events on cancer and nutrition.  Additionally, patients at high risk for a hereditary cancer syndrome are referred to the Breast Cancer Prevention Program, the Ovarian Cancer Screening Clinic, and the Familial Melanoma Clinic, when appropriate.

A mobile mammography program, operated by UCSF and San Francisco General Hospital Medical Center, provides early breast cancer detection for thousands of underserved Bay Area women. The mammovan, which is the first in the world to be equipped with high-diagnostic–quality digital mammography, travels to community health clinics across the city, providing about 30 mammograms daily. Foundation support pays for exams when women cannot afford the service. The UCSF Cancer Risk Program offers free monthly cancer risk education sessions for families with high rates of breast and ovarian cancer who are interested in counseling for genetic risk.


Support Services

UCSF's Cancer Resource Center (415.885.3693) sponsors more than two dozen patient support groups and weekly classes. Support groups are targeted to patients on the basis of cancer diagnosis; age-specificity; and cultural or language groups, including Russian, Spanish, Cantonese, and Mandarin. In addition, the Cancer Resource Center offers a Peer Support Program, Benefits and Health Insurance Counseling and Information services, and community education programs. 

A full-time nutritionist provides individual dietary counseling to cancer outpatients as well as to the interested public.  Nutritionists on staff with the UCSF Medical Center are available to inpatients with special needs.

Psychologists and social workers are available in all oncology areas for individual patient and family counseling. Other support services include:  Art for Recovery (415.885.7221), an expressive arts program offered to anyone dealing with cancer, which offers workshops, community projects, and a music series, and a Spiritual Care Program (415.885.7785), in which counseling and guidance assists patients and their families with questions about life and death.


Supportive Care

Pain Service

Pain services are provided through the UCSF Medical Center Pain Management Program, available at 415.885.7246. The program employs physicians and therapists with specialties in anesthesiology, neurology, psychiatry, nursing, pharmacy, psychology, internal medicine, and physical therapy.

Palliative/Supportive Service, Home Care/Hospice Service, and Rehabilitation Service

Available through the UCSF Medical Center

Cooperative Group Membership

Cooperative Group Membership List

  • ACOS-OG
  • COG
  • RTOG
  • NSABP
  • NMDP
  • ACRIN
  • NABTC
  • PBTC
  • CALGB
  • GOG
  • AMC

Activities in Cooperative Group

Leadership roles for UCSF investigators in:

  • AMC (Lawrence Kaplan, MD)
  • NABTC (Michael Prados, MD)
  • COG (Katherine Matthay, MD, Chair Neuroblastoma Strategy Group and Assoc. Chair, Solid Tumors)
  • CALGB (Charles Linker, MD; Eric Small, MD; Alan Venook, MD; Robert Warren, MD)
  • RTOG (Mack Roach, MD, Minority Chair)

Average Number of Adult Clinical Trials

More than 200 active therapeutic clinical trials, with additional non-therapeutic studies.


Clinical and Research Efforts

Adult Oncology Program *

No. of Inpatient Beds
(Medical/Surgical)

No. of Admissions

Average Length of Stay (days)

No. of New Outpatients

No. of Oncologists (Medical and Surgical)

50**

n/a

oncology: 13.8
BMT: 25.6;
surgery: n/a

approx. 5,000

approx. 100***

*Estimates are for UCSF/Parnassus and UCSF/Mount Zion Medical Centers. UCSF also provides house staff and oncology services at San Francisco General Hospital Medical Center and the San Francisco Veterans Affairs Medical Center, for which numbers are not included here.

**Medical oncology only; does not include surgery.

***Includes medical, surgical, and radiation oncology. NOT full-time equivalents.


UCSF Helen Diller Family Comprehensive Cancer Center
Pediatric Oncology Services


Introduction

The pediatric oncology program at UCSF is renowned for delivery of comprehensive multidisciplinary care to children and adolescents with cancer. Pediatric oncologists incorporate the expertise of multiple specialists such as pediatric surgeons, pediatric radiation therapists, pediatric rehabilitation, pediatric radiologists, child play therapists, school liaisons, and nurse practitioners. This multidisciplinary team is dedicated to providing comprehensive physical and psychosocial care to families learning about and living with the illness.

The pediatric oncology faculty members are highly trained in translational and laboratory research as well as state-of-the-art clinical care and are internationally renowned for helping to promote advances in the understanding and treatment of childhood cancer.

Special Expertise

  • Bone Marrow Transplantation
  • Bone Tumors
  • Brain Tumors
  • Late Effects
  • Leukemia
  • Neuroblastoma
  • Resistant Cancers and New Agents
  • Retinoblastoma
  • Soft Tissue Sarcoma


General Information

Pediatric Line

415.476.3831

Location

San Francisco, California

Physical Plant

UCSF Medical Center is a state-of-the-art health care facility with a 20-bed unit dedicated to inpatient cancer care and an additional six-bed unit for accommodating compromised host for children undergoing bone marrow and stem cell transplantation. Specialized nurses trained in the care of pediatric cancer patients staff the units. Outpatients are treated in an adjacent ambulatory care center that is associated with a pediatric day treatment center for administration of outpatient chemotherapy and transfusions.

Travel Assistance

UCSF will help to coordinate travel.

Lodging

Social workers assist in lodging arrangements for families. Two separate Family House facilities specifically for the families of children undergoing cancer treatment are located near the hospital.

Social Support

A social worker is available to every family of pediatric cancer patients. In addition, there is a nurse educator specialist who liaisons with the patient’s school. There is also an inpatient school facility, an active Child Life program, and a summer camp for Bay Area children with cancer.

Financial Assistance

Financial assistance is available.

Home Health Care

In-house home health services are available for pediatric oncology patients.

Ages Treated

Infants, children, and young adults up to age 30.


Clinical and Research Information

Director of Oncology Program

Katherine K. Matthay, MD

Operate Multidisciplinary Teams

Each patient has an assigned attending physician, social worker, and nurse practitioner who work with the child and family from diagnosis through long-term follow-up. Surgeons and radiotherapists are an integral part of the care.

Cooperative Group Membership

Children’s Oncology Group (COG)—Katherine K. Matthay, PI and member

Neuroblastoma Strategy Group, Executive Committee and Scietific Council;

New Approaches to Neuroblastoma Therapy—Katherine K. Matthay, PI

Pediatric Brain Tumor Consortium—Michael Prados, PI

Therapeutic Advances in Childhood Leukemia—Mignon Loh, PI

Average Number of Pediatric Clinical Trials

70

Pediatric Clinical Trial Coordinator

Sharon Lee — 415.514.3658


Special Expertise

Bone Marrow Transplantation

UCSF has a very active pediatric bone marrow transplantation program, with expertise in transplants for immuno-deficiency disorders as well as neuroblastoma and other solid tumors. The program provides transplants using a variety of stem cell sources including:

  • Autologous
  • Purged autologous with tumor cell removal
  • Unpurged peripheral blood stem cells
  • Autologous transplants including both bone marrow and peripheral blood stem cells from related and unrelated donors
  • Matched unrelated donors
  • Partial mismatches with stem cell manipulation
  • Cord blood transplants

Bone Tumors

The UCSF pediatric oncology program has an established multidisciplinary program in bone tumors led by international experts in pediatric oncology, radiation oncology, orthopedic oncology, and pathology. There is a strong commitment to optimal individualized tumor management with preservation of maximum function. Particular strengths of the UCSF program include new techniques for limb salvage surgery, as well as its pediatric radiotherapy department, orthotics, and physical therapy. A multidisciplinary pediatric bone clinic is held four times per year.

Brain Tumors

UCSF is renowned for its basic research as well as its multidisciplinary pediatric brain tumor program. The Brain Tumor Research Institute is dedicated to developing new treatments as well as finding the causes of childhood brain tumors. In addition, world-renowned neurosurgeons and expert radiotherapists support the program. It also includes a gamma-knife facility for the treatment of brain tumors. A dedicated pediatric neuro-oncologist directs the multidisciplinary program for children. A National Cancer Institute Program Project Grant helps to support the multidisciplinary research involved in this program. In addition, UCSF has become part of the NCI Pediatric Brain Tumor Consortium for testing new treatments.

Late Effects

The pediatric group at UCSF is part of a national study of 25,000 survivors of childhood cancer and places special emphasis on the assessment of cardiac, pulmonary, and neurocognitive late effects. Our Childhood Cancer Survivor Clinic follows patients at regular intervals after therapy with appropriate patient education and systematic surveillance for possible organ toxicities, secondary malignancy, and quality of life.

Leukemia

Investigators at UCSF are known for the molecular investigation in the causes of myeloblastic leukemia and myelodysplasia. They have also established national studies of these disorders to improve the outcome for children with leukemia. We are leaders in the biology and therapy of all childhood leukemias.

Neuroblastoma

Investigators at UCSF are internationally renowned for their research in the molecular biology of neuroblastoma as well as for testing novel treatments including tumor-targeted I-131 MIBG therapy, purged bone marrow transplantation, and new chemotherapeutic agents. UCSF has become a center for consultation for this devastating childhood tumor, and leads a national consortium for testing new therapies.

Resistant Cancers and New Agents

UCSF has an NIH-funded pediatric clinical research center that is dedicated, in part, to testing new therapies for children with advanced refractory cancer. Novel anti-cancer agents including monoclonal antibodies or immunotoxins specifically directed against cancers, differentiating agents to induce tumor growth arrest, targeted radiotherapy, and other new cancer chemotherapeutic drugs are administered to children with refractory cancer. In addition, important laboratory/clinical efforts directed at elucidating and overcoming mechanisms of drug resistance  are an important part of the Pediatric Oncology program.

Retinoblastoma

UCSF is one of the premier centers in the country for treatment of this rare pediatric eye tumor. UCSF offers both basic research programs and a dedicated pediatric ophthalmologic oncologist who coordinates the specialized care of these children through a multidisciplinary retinoblastoma program with participation of geneticists, prosthetist, craniofacial surgery, radiotherapy, endocrinology, pediatric oncology, and a school liaison nurse. The expert multimodality approach taken to these eye tumors can frequently save vision in these children.

Soft Tissue Sarcoma

UCSF has helped to pilot intensive therapies for children with metastatic sarcomas including autologous bone marrow transplantation. In addition, investigators from UCSF are leaders in the development of new national Intergroup Ewing Sarcoma studies.


Statistics

Percent of children treated in each age range

Age Range

0–1

2–5

6–12

13+

Percent Treated

17%

27%

29%

27%

Pediatric Oncology Program, 2004

No. of Inpatient Beds

No. of Admissions

Average Length of Stay(days)

No. of New Outpatients

Total Outpatient Visits

No. of Bone Marrow Transplants

No. of Oncologists

29

1,000

5.5

143

4,000

60

12


UCSF Helen Diller Family Comprehensive Cancer Center
Genetic Counseling and Testing Service

The UCSF Helen Diller Family Comprehensive Cancer Center operates a Cancer Risk Assessment Program (CRP) that provides genetic counseling, risk assessment, and genetic testing for individuals from families with a high risk of heritable cancer. The Cancer Risk Program is composed of five individual clinics and a consult service to provide comprehensive care for hereditary cancers across all organ systems: 

  • The Breast Cancer Prevention Clinic within the Carol Franc Buck Breast Care Center.
  • The Familial Gynecologic Cancer Clinic within the Gynecologic Oncology Department.
  • The Familial Gastrointestinal Genetics Clinic within the Department of Medicine.
  • The Familial Melanoma Clinic within the Department of Dermatology.
  • The Familial Prostate Cancer Clinic within the Department of Urology.

The CRP’s main focus is on breast/ovarian cancer syndromes, colorectal cancer (hereditary non-polyposis colorectal cancer, or HNPCC), and related malignancies. The multidisciplinary consultation service provides genetic counseling and risk assessment to cancer patients whose families exhibit the characteristics of hereditary cancer.  This includes recommendations for genetic counseling and risk assessment for individuals at high risk in these families.  The Cancer Risk Assessment team includes individuals trained in oncology, gastroenterology, genetics, epidemiology, urology, dermatology, genetic counseling, and nursing.

Location

UCSF Medical Center/Mt. Zion, San Francisco CA

Program Director

John L. Ziegler, MD, MSc

Research Director

Jane McLennan, MD, PhD

Physician Consultants

Mary Beattie, MD; Jeffrey Tice, MD; Lee-may Chen, MD; Bethan Powell, MD; Mindy Goldman, MD; Laura Esserman, MD, MBA; Alan Glassberg, MD; Peter Carroll, MD; Hope Rugo, MD; Shelley Hwang, MD; Judith Luce, MD; Mohammed Kashani-Sabet, MD; Marc Shuman, MD; Robert Nussbaum, MD

Genetic Counselors

Beth Crawford, MS (Director of Clinical Services)
Robin Lee, MS, CGC
Peggy Conrad, MS, CGC
Kate Lamvik, MS
Julie Mak, MS, CGC
Nicola Stewart, MS, CGC
Amie Blanco, MS, CGC

To Schedule Appointments

415.885.7779

 

The components of the comprehensive services provided by the Cancer Risk Team include:

Intake Process

Physician and Community Awareness

A free monthly education session is offered to the public at the Cancer Center by a genetic counselor. This session is devoted specifically to community education and outreach about heritable susceptibility to cancer. In addition, the counseling and physician team hold regular training and education seminars for health care professionals in the Bay area. The Medical Genetics fellowship course, seminar, and conference structure includes information about cancer genetics and related topics.

Patient Education

Individuals from families with a strong history of cancer may wish to learn more about their individual risk for cancer and about the potential risk to other family members, including offspring. Generally, heritable susceptibility to cancer is suspected when cancer occurs at young ages and in more than one generation. It is more common in these families for family members to be diagnosed with more than one type of cancer. Questionnaires detailing the patient's personal and family medical history are sent at the time of scheduling and are asked to be returned prior to their scheduled appointment for the most accurate consultation.

For new clients, counselors take a detailed family history and educate the client about hereditary cancer, gene mutations, and cancer susceptibility for family members. If the family cancer history has an hereditary pattern, medical records are requested to confirm the cancer diagnoses and a second appointment is arranged to discuss genetic testing. Financial arrangements (insurance coverage or private payment) and confidentiality provisions are an important part of the intake process.

Referral

Patients are referred by both physicians within the UCSF Medical Center and Cancer Center as well as community physicians. Referring physicians have a variety of backgrounds, including oncology, surgery, gynecology, internal medicine, dermatology, and gastroenterology. A large number of patients are self-referred because of a strong family cancer history. Physicians or patients can access the Cancer Genetic Risk Assessment Services by calling the scheduling number.

Identifying Eligible Subjects

Individuals who may benefit from a referral include those with family members with multiple primary cancers, cancer with an unusually young age of onset, or a clustering of rare or unusual cancers in the family. Referrals also include individuals with cancers occurring in association with a known genetic condition such as:

  • Neurofibromatosis, Fanconi Anemia, and Tuberous Sclerosis
  • Any known cancer susceptibility syndrome, such as:
    • Lynch Syndrome (Hereditary Non-polyposis Colorectal Cancer)
    • Familial Adenomatous Polyposis
    • Hereditary Breast-Ovarian Cancer Syndrome
    • Li-Fraumeni Syndrome
    • von Hippel-Lindau Syndrome
    • Multiple Endocrine Neoplasia
    • Familial Melanoma

Pre-test Counseling and Risk Assessment

This visit includes:

  • A detailed analysis and evaluation of the family medical history
  • A discussion of the specific hereditary cancer syndromes
  • An assessment of the patient’s cancer risk based on their family and/or personal history of cancer using several statistical models
  • Tailored recommendations for appropriate screening, prevention, and early detection
  • Cases are reviewed by a multidisciplinary team of physicians and genetic counselors at a weekly Cancer Genetics Tumor Board

Informed Consent Procedures

Patients who elect to proceed with genetic testing for cancer susceptibility will be required to sign a consent form approved by the UCSF IRB.


Testing

Confidentiality Standards

The Cancer Risk Program maintains strict confidentiality.. For those patients that are seen in the Breast and Ovarian or Colorectal Clinics of the Cancer Risk Program and elect testing, the results of their genetic tests will be kept in a separate and confidential file. Genetic testing results and documentation of a consultation will be disclosed to a third party only with the written consent of the patient.

Testing

For those patients electing genetic testing for cancer susceptibilities, in most cases the sample is sent for testing to a licensed, CLIA approved commercial laboratory. Testing for the three common mutations in BRCA 1 and 2 is available at the UCSF Molecular Diagnostic Laboratory.

Available Testing at or Through UCSF Helen Diller Family Comprehensive Cancer Center

Cancer/Syndrome

Gene

Breast and Ovarian Cancer *

BRCA1 & BRCA2

Familial Adenomatous Polyposis

APC

Hereditary Nonpolyposis Colon Cancer**

hMLH1 & hMSH2

Hereditary Melanoma

CDKN2A

Li Fraumeni 

p53

 

*For clients of Jewish ancestry, testing may be limited to the three founder mutations; full sequencing is used for all others.

**Clients may undergo screening of a colorectal tumor for microsatellite instability (a marker of missense repair gene mutations). If high-level MSI is detected, sequencing is undertaken.

Test Result Interpretation

The test result is interpreted by the physician and genetic counselor involved with the patient's consultation. The result is interpreted based on the findings of the laboratory, published information about the mutation and condition, and the patient's personal and family history. A letter summarizing the details of our consultation and our recommendations is sent to the patients for their records and to the referring physician.


Post-Test Counseling and Follow-Up

Post-Test Counseling

The test result is usually available in two to four weeks, and an individual appointment with the counselor is devoted to interpreting the result. Clients are given guidelines for further medical surveillance, and consult with a trained physician to learn about prevention options.

Medical and Surgical Management

Patients may be referred to the UCSF Carol Frank Buck Breast Care Center, the Familial Gynecologic Cancer Clinic, and the Melanoma Prevention Clinic where they are offered a myriad of surveillance and treatment options, including the opportunity to enroll in clinical prevention trials, if eligible.


Research

All patients in the Program are asked to read and sign an informed consent, approved by the UCSF Human Subjects Review Committee. In addition to routine surveillance recommendations, several research programs at the UCSF Helen Diller Family Comprehensive Cancer Center address issues for high-risk patients.  In addition to offering clinical genetic counseling/testing services, the Cancer Center includes a Familial Cancer Risk Core that provides researchers with access to a database of genotyped probands (hereditary breast/ovarian/colorectal cancer) and clinical specimens with correlative epidemiologic data.

Last updated: 2/20/2008

 

Educational Opportunities

NCCN 1st Annual Forum: Innovative Diagnostics & Therapeutics in Cancer Care™

September 4, 2008
New York Marriott at the Brooklyn Bridge
New York, New York

NCCN 3rd Annual Congress: Hematologic Malignancies™

September 5 – 6, 2008
New York Marriott at the Brooklyn Bridge
New York, New York


Exhibitor Information


NCCN Regional Guidelines Symposia

NCCN Non-Small Cell Lung Cancer Guidelines Symposium
Birmingham, Michigan (Friday, September 12, 2008)

NCCN Breast Cancer Guidelines Symposium
Durham, North Carolina (Monday, September 22, 2008)

NCCN Colon and Rectal Cancers Guidelines Symposia
New York , New York (Tuesday, September 23, 2008)

NCCN Head and Neck Cancers Guidelines Symposia
Omaha, Nebraska (Friday, October 10, 2008)

NCCN Breast Cancer Guidelines Symposium
Tampa, Florida (Monday, October 20, 2008)

NCCN Non-Small Cell Lung Cancer Guidelines Symposium
Durham, North Carolina (Monday, November 03, 2008)

NCCN Prostate Cancer Guidelines Symposia
Philadelphia, PA (Wednesday, November 05, 2008)

NCCN Head and Neck Cancers Guidelines Symposia
Houston, Texas (Tuesday, November 11, 2008)

More Events ....


NCCN International

Chinese – 中文

Japanese –日本語

NCCN Privacy Policy NCCN Legal Disclaimer NCCN Site Map Contact NCCN Home National Comprehensive Cancer Network